EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Low-Level Viremia among Adults Living with HIV on Dolutegravir-Based First-Line Antiretroviral Therapy Is a Predictor of Virological Failure in Botswana

Ontlametse T Bareng, Sikhulile Moyo iD, Mbatshi Mudanga, Kagiso Sebina, Catherine K Koofhethile, Wonderful T Choga, Natasha O Moraka iD, Dorcas Maruapula iD, Irene Gobe, Modisa S Motswaledi, Rosemary Musonda, Bornapate Nkomo und 7 weitere

Viruses · 01.05.2024 · 16 (5) · 720

DOI: 10.3390/v16050720 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Viruses, online erschienen am 01.05.2024. Verfasst von Ontlametse T Bareng und 18 weiteren Autor:innen. Beteiligte Einrichtung: Botswana Harvard Health Partnership, Gaborone 0000, Botswana. Hauptthemen laut MEDLINE: HIV Infections, Pyridones, Heterocyclic Compounds, 3-Ring, Oxazines. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: FIC NIH HHS, Bill & Melinda Gates Foundation, NIAID NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We evaluated subsequent virologic outcomes in individuals experiencing low-level virem ia (LLV) on dolutegravir (DTG)-based first-line antiretroviral therapy (ART) in Botswana. We used a national dataset from 50,742 adults who initiated on DTG-based first-line ART from June 2016–December 2022. Individuals with at least two viral load (VL) measurements post three months on DTG-based first-line ART were evaluated for first and subsequent episodes of LLV (VL:51–999 copies/mL). LLV was sub-categorized as low-LLV (51–200 copies/mL), medium-LLV (201–400 copies/mL) and high-LLV (401–999 copies/mL). The study outcome was virologic failure (VF) (VL ≥ 1000 copies/mL): virologic non-suppression defined as single-VF and confirmed-VF defined as two-consecutive VF measurements after an initial VL < 1000 copies/mL. Cox regression analysis identified predictive factors of subsequent VF. The prevalence of LLV was only statistically different at timepoints >6–12 (2.8%) and >12–24 (3.9%) (p-value < 0.01). LLV was strongly associated with both virologic non-suppression (adjusted hazards ratio [aHR] = 2.6; 95% CI: 2.2–3.3, p-value ≤ 0.001) and confirmed VF (aHR = 2.5; 95% CI: 2.4–2.7, p-value ≤ 0.001) compared to initially virally suppressed PLWH. High-LLV (HR = 3.3; 95% CI: 2.9–3.6) and persistent-LLV (HR = 6.6; 95% CI: 4.9–8.9) were associated with an increased hazard for virologic non-suppression than low-LLV and a single-LLV episode, respectively. In a national cohort of PLWH on DTG-based first-line ART, LLV > 400 copies/mL and persistent-LLV had a stronger association with VF. Frequent VL testing and adherence support are warranted for individuals with VL > 50 copies/mL.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HIV InfectionsPyridonesHeterocyclic Compounds, 3-RingOxazinesViral LoadPiperazinesViremiaHumansMaleBotswanaFemaleAdultMiddle AgedHIV-1Treatment FailureAnti-HIV AgentsAntiretroviral Therapy, Highly ActiveHIV Integrase InhibitorsDolutegravir

Stichwörter der Autor:innen

Botswanadolutegravir-based first line antiretroviral therapylow level viremiapeople living with HIV

Substanzen

PyridonesHeterocyclic Compounds, 3-RingOxazinesPiperazinesAnti-HIV AgentsHIV Integrase InhibitorsDolutegravir

Autor:innen und Institutionen

  • Botswana Harvard Health Partnership, Gaborone 0000, Botswana.
  • Department of Medical Sciences, Faculty of Allied Health Professions, University of Botswana, Gaborone 0022, Botswana.
  • Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA.
  • Department of Pathology, Division of Medical Virology, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town 7935, South Africa.
  • School of Health Systems and Public Health, Faculty of Health Sciences, University of Pretoria, Pretoria 0028, South Africa.
  • Department of Strategic Information, Botswana-University of Maryland School of Medicine Health Initiative, Gaborone 0022, Botswana.

ORCID-Profile: Sikhulile Moyo, Natasha O Moraka, Dorcas Maruapula

Förderung

  • FIC NIH HHS
  • Bill & Melinda Gates Foundation
  • NIAID NIH HHS
  • NHGRI NIH HHS
  • Fogarty International Center at the US National Institutes of Health
  • Sub-Saharan African Network for TB/HIV Research Excellence (SANTHE 2.0)
  • H3ABioNet
  • US National Institutes of Health NIH

Zitieren

APA

Bareng, O. T., Moyo, S., Mudanga, M., Sebina, K., Koofhethile, C. K., Choga, W. T., Moraka, N. O., Maruapula, D., Gobe, I., Motswaledi, M. S., Musonda, R., Nkomo, B., Ramaabya, D., Chebani, T., Makuruetsa, P., Makhema, J., Shapiro, R., Lockman, S., & Gaseitsiwe, S. (2024). Low-Level Viremia among Adults Living with HIV on Dolutegravir-Based First-Line Antiretroviral Therapy Is a Predictor of Virological Failure in Botswana. Viruses, 16(5), 720. https://doi.org/10.3390/v16050720

Vancouver

Bareng OT, Moyo S, Mudanga M, Sebina K, Koofhethile CK, Choga WT, et al. Low-Level Viremia among Adults Living with HIV on Dolutegravir-Based First-Line Antiretroviral Therapy Is a Predictor of Virological Failure in Botswana. Viruses. 2024;16(5):720. doi:10.3390/v16050720

BibTeX
@article{Bareng2024,
  author = {Bareng, Ontlametse T and Moyo, Sikhulile and Mudanga, Mbatshi and Sebina, Kagiso and Koofhethile, Catherine K and Choga, Wonderful T and Moraka, Natasha O and Maruapula, Dorcas and Gobe, Irene and Motswaledi, Modisa S and Musonda, Rosemary and Nkomo, Bornapate and Ramaabya, Dinah and Chebani, Tony and Makuruetsa, Penny and Makhema, Joseph and Shapiro, Roger and Lockman, Shahin and Gaseitsiwe, Simani},
  title = {Low-Level Viremia among Adults Living with HIV on Dolutegravir-Based First-Line Antiretroviral Therapy Is a Predictor of Virological Failure in Botswana},
  journal = {Viruses},
  year = {2024},
  volume = {16},
  number = {5},
  pages = {720},
  doi = {10.3390/v16050720}
}
Kostenlos starten →